Prothena reported 0 in Loan Capital for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Acadia Pharmaceuticals ACAD:US $ 0M 0M
Agios Pharmaceuticals AGIO:US $ 0.28M 0M
Akebia Therapeutics AKBA:US $ 0M 0M
ALKERMES ALKS:US 292.17M 633K
Alnylam Pharmaceuticals ALNY:US $ 676.71M 1.01M
Amgen AMGN:US $ 36010M 2788M
Biogen BIIB:US $ 6275.7M 1.7M
Biomarin Pharmaceutical BMRN:US $ 1080.06M 0.98M
Bluebird Bio BLUE:US $ 0M 0M
Exelixis EXEL:US $ 0M 0M
Intercept Pharmaceuticals ICPT:US $ 716.88M 177.1M
Intra Cellular Therapies ITCI:US $ 0M 0M
IONIS PHARMACEUT IONS:US $ 1247.93M 19.91M
Macrogenics MGNX:US $ 0 0
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 377.7M 42.6M
Prothena PRTA:US 0 0
Regeneron Pharmaceuticals REGN:US $ 2700.4M 720.4M
Seattle Genetics SGEN:US $ 0M 0M
Ultragenyx Pharmaceutical RARE:US $ 0M 0.41M
Vertex Pharmaceuticals VRTX:US $ 495.5M 14.3M
Vital Therapies VTL:US $ 0M 0M
Xoma XOMA:US $ 0 0
YTE INCY:US $ 31.38M 0.25M